THANK YOU FOR SUBSCRIBING


Mario Michael Schmidt, CEO, Annette Brandau, CEO and Thomas Brandau, CEOSLYHEALTH, a dynamic and independent healthcare marketing agency is making waves in the healthcare marketing landscape. Dedicated exclusively to the healthcare sector, SLYHEALTH has positioned itself as a leader in supporting high-impact product launches across Europe, with a focus on the key market Germany. Through its results-oriented communication strategies and deep market knowledge, it helps pharmaceutical and biotech companies connect with key decision makers and physicians and optimize their products’ path to prescription.
Drawing from its deep expertise, SLYHEALTH specializes in key healthcare segments, including vaccines, oncology, rare diseases and cardiology. Its role in supporting notable product launches within these critical areas has made it an industry pioneer.
Tailored Strategies for Product Launches
With an independent and innovative approach, SLYHEALTH offers tailored strategies for healthcare marketing. Its commitment to delivering customized solutions ensures that clients receive the support and strategies they need to achieve successful product launches.
Operating within stringent regulatory frameworks, SLYHEALTH’s expertise enables it to work closely with medical, legal and compliance professionals. This collaboration ensures that strategies meet global regulatory standards while upholding ethical considerations.
Standing at the forefront of market innovation, SLYHEALTH takes full responsibility for client success, prioritising their achievements above all else.
SLYHEALTH’s success is built on collaboration. By partnering with various specialists and assembling cross-functional teams of experienced professionals, SLYHEALTH crafts effective content and marketing campaigns that resonate with healthcare professionals.
“We bring uniquely tailored strategies to the table to guarantee successful Rx product launches for our clients”, says Annette Brandau, CEO of SLYHEALTH.
When beginning a new project, the agency rejects a one-size-fits-all approach and foregoes a standardised onboarding process, embracing adaptability and flexibility throughout its operational model. It conducts thorough evaluations of the disease, product, and market dynamics, coupled with an understanding of the client’s market positioning, digital capabilities, processes, and overall capabilities.
It assembles a customised cross-functional team comprising highly experienced internal and external professionals who bring extensive expertise and passion to a project. This includes qualified individuals from consulting, medicine, strategy development, conceptualisation, creative services and digital marketing. If required, teams can be scaled up to 100 members, even within a short period.
Acting as the lead agency in every project, SLYHEALTH coordinates the work of this unique blend of staff to craft tailored content and powerful marketing campaigns. These initiatives are designed to resonate with an HCP’s underlying needs.
“With our staff, external specialists, and service partners, we can create the perfect setup for each project need and outcome”, says Thomas Brandau, CEO of SLYHEALTH.
Believing that the best way to achieve positive results is through honest partnership, SLYHEALTH emulates this philosophy during client interactions and works with them in close collaboration during the project lifecycle.
Adapting to Changing Circumstances
Constantly driven to think beyond conventional boundaries and pioneer innovative marketing strategies, it steers projects toward triumph in any situation. For instance, amid the unfavourable circumstances that emerged due to the COVID-19 pandemic, SLYHEALTH was a pivotal force. It supported local and international biotech and pharmaceutical companies in some of Europe’s most important and promising product launches in the areas of vaccines, cancer, rare diseases, and health tech.
Digital Transformation: From Tactics to Strategy
Most pharmaceutical companies have invested in brand websites or HCP portals for many years. They have become a standard part of the go-to-market strategy. Since the COVID-19 pandemic, there has been an increased focus on e-detailing, email marketing, online conference, and other digital media.
While budgets are allocated for omnichannel tactics, there is rarely an overarching strategy that links digital activities to business outcomes.
Crafting Effective Launch Communication![]()
We bring uniquely tailored strategies to the table to guarantee successful Rx product launches for our clients
Effective communication is just one part of the equation for a successful Rx product launch, with the technical setup and delivery of customised content to each HCP also playing a critical role.
It acknowledges that HCPs have diverse preferences for content types and formats. These preferences are influenced by their busy schedules, specific clinical requirements, practice settings, specialities, personal lifestyles and professional expectations.
In an industry characterised by stringent regulations and narrow marketing opportunities, SLYHEALTH is creating opportunities for its clients to succeed, delivering customised solutions that drive customer-centric results and allow it to build a distinctive reputation in the field.
Excellence in Commercial Communication
With a track record of achievement, SLYHEALTH’s commitment to innovation and collaboration has resulted in a collection of successful healthcare marketing endeavors. Its legacy is characterized by its dedication to excellence and impactful results. In the realm of healthcare marketing, SLYHEALTH stands as a reliable partner, offering strategic support and tailored solutions that pave the way for successful product launches in Europe and beyond.
Company
SLYHEALTH
Management
Mario Michael Schmidt, CEO, Annette Brandau, CEO and Thomas Brandau, CEO
Description
SLYHEALTH is a dynamic and independent German healthcare marketing agency. With a strong industry focus, they have established themselves as leaders in supporting high impact product launches in Europe in areas such as vaccines, oncology and rare diseases.